why choose us

First received: October 31, 2022

Clinical Trial: Pilot of Osanetant to Reduce Testosterone in Men With Adenocarcinoma of the Prostate

Study Status: Completed

Recruit Status: RECRUITING

Condition: Prostate Adenocarcinoma

Study Type: INTERVENTIONAL


Official Title: Pilot of Osanetant to Reduce Testosterone in Men With Adenocarcinoma of the Prostate (PORT-MAP)

Brief Summary: To evaluate the effect of Osanetant on testosterone levels in men with prostate cancer within 28 days of therapy.

Read more